We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301
News

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301
News

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CDX-301 is soluble, recombinant human FMS-like tyrosine kinase 3 ligand (Flt3L) and previous experience has shown that it increases the numbers and activity of blood stem cells and immune cells.
CDX-301 is a potent stem cell mobilizer and dendritic cell growth factor. While there are multiple possible indications for CDX-301, Celldex's first priority is to develop this molecule for hematopoietic stem cell transplant, where it has demonstrated improvement of blood cell reconstitution in preclinical in vivo models.

The Phase 1 study of CDX-301 is a dose-escalating clinical trial aimed at determining the appropriate dose for further development based on safety, tolerability and biological activity. The trial will evaluate seven different dosing regimens of CDX-301 and will accrue approximately 30 healthy subjects at Rockefeller University.

"This clinical trial represents the first step in the continued clinical development of this biologically active molecule," said Thomas Davis, M.D., Chief Medical Officer of Celldex Therapeutics. "In particular, we believe that CDX-301 has significant potential to be developed in a number of indications in cancer, inflammatory and infectious diseases."

Advertisement